New targeted drug combo aims to curb relapse in kids with rare immune disorder
NCT ID NCT07431060
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding the targeted drug luvometinib to standard chemotherapy improves outcomes for children with multisystem Langerhans cell histiocytosis (LCH), a rare immune cell disorder. About 120 children aged 0-18 with newly diagnosed, untreated LCH will be randomly assigned to receive either standard chemo alone or chemo plus luvometinib. The goal is to see if the combination reduces disease reactivation and improves survival without major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Luvometinib (a targeted cancer drug) plus chemotherapy (prednisone, vincristine, mercaptopurine)
What this could lead to
If successful, this combination could offer better disease control and fewer relapses for children with severe multisystem LCH.
What could go wrong
This is an early-stage trial with only 120 participants, so results may not apply to all children. Adding a targeted drug may also increase side effects like skin issues or high triglycerides.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Anhui Provincial Children's Hospital
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangxi Provincial Children's Hospital
RECRUITINGJiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kunming Children's Hospital
RECRUITINGKunming, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xinjiang Medical University
RECRUITINGÜrümqi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Second Hospital, Sichuan University
RECRUITINGChengdu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xi'an Children's Hospital
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xi'an Northwest Women's and Children's Hospital
RECRUITINGXi'an, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital
RECRUITINGZunyi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••